Sophiris Bio Inc (SPHS) 2.00 $SPHS Sophiris Bio Reports

New Post Public Reply Private Reply Replies (0) Message Board

Nov 17, 2015 at 3:13 PM

Sophiris Bio Inc (SPHS) 2.00 $SPHS

Sophiris Bio Reports Third Quarter Financial Results and Business Highlights
PR Newswire - Mon Nov 16, 3:01PM CST
Sophiris Bio Inc. (NASDAQ: SPHS) (the "Company" or "Sophiris"

, a biopharmaceutical company developing PRX302 (topsalysin) for the treatment of urological diseases, today announced financial results for the three and nine months ended September 30, 2015.
SPHS: 2.00 (-0.33)

Biotech Stock Mailbag: Relypsa, Sophiris, Bluebird, Zafgen, NW Bio
at The Street - Fri Nov 13, 8:36AM CST
Biotech columnist Adam Feuerstein answers readers' questions about health care.
BLUE: 80.16 (+5.71), ZFGN: 14.62 (-0.10), NWBO: 4.46 (+0.03), ZSPH: 89.51 (+0.02), SPHS: 2.00 (-0.33), RLYP: 18.52 (+0.04)

Sophiris Bio (SPHS) Stock Jumps After Drug Trial Meets Goal
at The Street - Wed Nov 11, 2:34PM CST
Sophiris Bio (SPHS) stock is increasing on heavy trading volume on Wednesday, after the company announced that its prostate drug met the goal of a Phase 3 study.
SPHS: 2.00 (-0.33)

Sophiris Bio Phase 3 BPH Study Successfully Meets Primary Endpoint
PR Newswire - Tue Nov 10, 7:18AM CST
Sophiris Bio Inc. (NASDAQ: SPHS) (the "Company" or "Sophiris"

, a biopharmaceutical company developing PRX302 (topsalysin) for the treatment of urological diseases, today announced final results from its Phase 3 "PLUS-1" study of PRX302 as a treatment for lower urinary tract symptoms of benign prostatic hyperplasia (BPH, enlarged prostate). PRX302 demonstrated a statistically significant improvement in International Prostate Symptom Score (IPSS) total score from baseline over 12 months compared to the vehicle-only control group (7.60 vs. 6.58 point overall improvement; p = 0.043), the primary endpoint of the study. PRX302 continues to demonstrate a favorable safety profile, with no evidence of any treatment related sexual or cardiovascular side effects.
SPHS: 2.00 (-0.33)

Versartis names Dr Lars Ekman as global development advisor
M2 - Fri Sep 11, 4:58AM CDT
Biopharmaceutical company Versartis (NasdaqGS:VSAR) revealed on Thursday that it has appointed Lars Ekman, MD, PhD, as its global development advisor.
VSAR: 10.15 (-0.20), SPHS: 2.00 (-0.33), ONCE: 51.80 (-0.20)

Sophiris Bio Reports Second Quarter Financial Results
Business Wire - Thu Aug 13, 3:01PM CDT
Sophiris Bio Inc. (NASDAQ: SPHS) (the "Company" or "Sophiris"

, a biopharmaceutical company developing PRX302 (topsalysin) for the treatment of urological diseases, today announced financial results for the three and six months ended June 30, 2015.
SPHS: 2.00 (-0.33)

5 Breakout Stocks Under $10 Set to Soar
at The Street - Thu Aug 06, 10:45AM CDT
These under-$10 stocks look ready to soar higher from current levels.
HIVE: 5.87 (-0.08), SPHS: 2.00 (-0.33), MOBL: 3.93 (-0.10), SIXD: 2.90 (unch), PRSN: 0.55 (-0.01)

Drugs - Generic Equities Coverage -- Oculus Innovative Sciences, Medicines, Supernus Pharma, Sophiris Bio, and Rigel Pharma
PR Newswire - Wed Aug 05, 8:35AM CDT
Equity Research Institute has initiated coverage on the following equities: Oculus Innovative Sciences Inc. (NASDAQ: OCLS), The Medicines Company (NASDAQ: MDCO), Supernus Pharmaceuticals Inc. (NASDAQ: SUPN), Sophiris Bio Inc. (NASDAQ: SPHS), and Rigel Pharmaceuticals Inc. (NASDAQ: RIGL). Free research report on Oculus Innovative Sciences can be accessed at https://www.EquityResearchInstitute.com/reports?keyword=OCLS On Tuesday, August 04, 2015, the NASDAQ Composite ended at 5,105.55, down 0.19%, the Dow Jones Industrial Average lost 0.27%, to finish the day at 17,550.69, and the S&P 500 closed at 2,093.32, down 0.22%. The losses were broad based as seven out of nine sectors ended the session in negative. Register for your complimentary reports at the links given below.
SPHS: 2.00 (-0.33), MDCO: 41.14 (-0.37), SUPN: 16.70 (+0.59), RIGL: 2.91 (-0.09), OCLS: 1.13 (-0.01)

Benign Prostatic Hyperplasia Pipeline Report 2015 - 26 Companies & 35 Drug Profiles
M2 - Fri Jul 10, 3:20AM CDT
Research and Markets (http://www.researchandmarkets.com/research/k3hn53/benign_prostatic) has announced the addition of the "Benign Prostatic Hyperplasia - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Benign Prostatic Hyperplasia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Benign Prostatic Hyperplasia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AbbVie Inc. - Addex Therapeutics Ltd - AmVac AG - AndroScience Corporation - Aphios Corporation - Ausio Pharmaceuticals, LLC - Biolab Sanus Farmaceutica Ltda. - Chong Kun Dang Pharmaceutical Corp. - Corium International, Inc. - Curadis GmbH - Euroscreen S.A. - Hanmi Pharmaceuticals, Co. Ltd. - IntelGenx Corp. - Jeil Pharmaceutical Co., Ltd. - KAEL-GemVax Co., Ltd. - Kaken Pharmaceutical Co., Ltd. - Meiji Seika Pharma Co., Ltd. - Mezzion Pharma Co. Ltd. - Neurocentrx Pharma Ltd. - Nymox Pharmaceutical Corporation - Ono Pharmaceutical Co., Ltd. - Quest PharmaTech Inc. - SK Chemicals Co., Ltd. - SOM Innovation Biotech SL - Sophiris Bio, Inc. - Yungjin Pharm Ind. Co., Ltd. Drug Profiles - (tamsulosin hydrochloride dutasteride) - ADX-68692 - AMV-110 - ASC-JM.X2 - AUS-131 - BL-214 - CKD-902 - CR-1493 - Drugs for Burning Sensation - ESN-364 - HCP-1303 - HIP-1402 - INT-0031 - JLP-1207 - L-1AD3 - MCS-2 - NCE-403 - NX-1207 - ONO-8430506 - S-40542 - SL-052 - Small Molecules to Antagonize GnRH for Women's Health, BPH and Oncology - Small Molecules to Inhibit Steroidal 5-Alpha Reductase for Benign Prostatic Hyperplasia - SOM-2391 - SOM-2393 - Sperol - Synthetic Peptide to Antagonize GPR54 for Womens Health, Male Health and Oncology - talaporfin sodium - tamsulosin hydrochloride - tamsulosin hydrochloride CR - tertomotide - topsalysin - udenafil - YBH-1603 - YOB-1604 For more information visit http://www.researchandmarkets.com/research/k3..._prostatic
CORI: 7.25 (+0.14), SPHS: 2.00 (-0.33), NYMX: 3.38 (+0.01), ABBV: 60.34 (+0.33)

Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Thu May 28, 8:16AM CDT

RALY: 19.49 (+0.01), KNDI: 9.93 (-0.39), EXPR: 16.73 (-0.44), MNGA: 1.11 (-0.01), SPHS: 2.00 (-0.33), NBS: 2.25 (-0.09), BIOC: 1.94 (-0.04), ONTY: 3.28 (-0.07), OHGI: 1.05 (-0.02), IMAX: 38.62 (+0.55), KNOP: 15.10 (-0.24), CERE: 0.93 (unch), DANG: 6.66 (-0.06), XOMA: 1.39 (+0.06)

Sophiris Bio to Present at the LD Micro Invitational Conference
Business Wire - Wed May 27, 3:01PM CDT
Sophiris Bio Inc. (NASDAQ: SPHS) (the "Company" or "Sophiris"

, a biopharmaceutical company developing PRX302 for the treatment of urological diseases, today announced that Randall E. Woods, president and chief executive officer, will present a corporate overview at the LD Micro Invitational Conference. The presentation is scheduled for Tuesday, June 2, 2015 at 11:30 a.m. PDT in Los Angeles.
SPHS: 2.00 (-0.33)

Sophiris Bio initiates mid-stage trial of lead product candidate PRX302
Seeking Alpha - at Seeking Alpha - Wed May 27, 12:39PM CDT

SPHS: 2.00 (-0.33)

Sophiris Bio admits first patients under Phase 2a proof of concept study of PRX302 in prostate cancer
M2 - Wed May 27, 4:17AM CDT
Biopharmaceutical company Sophiris Bio (NasdaqGM:SPHS) said on Tuesday that it has dosed the first patients in a Phase 2a proof of concept trial of PRX302 as a treatment for localized low to intermediate risk prostate cancer, the second most common form of cancer in men in the US with an estimated 220,800 new cases in 2015.
SPHS: 2.00 (-0.33)

Sophiris Bio Enrolls First Patients in Phase 2a Proof of Concept Prostate Cancer Study
Business Wire - Tue May 26, 7:00AM CDT
Sophiris Bio Inc. (NASDAQ: SPHS) (the "Company" or "Sophiris"

, a biopharmaceutical company developing PRX302 (topsalysin) for the treatment of urological diseases, today announced that the first patients have been dosed in a Phase 2a proof of concept trial of PRX302 as a treatment for localized low to intermediate risk prostate cancer.
SPHS: 2.00 (-0.33)

Sophiris Bio reports Q1 results
Seeking Alpha - at Seeking Alpha - Wed May 13, 3:48PM CDT

SPHS: 2.00 (-0.33)

Sophiris Bio Reports First Quarter Financial Results
Business Wire - Wed May 13, 3:01PM CDT
Sophiris Bio Inc. (NASDAQ: SPHS) (the "Company" or "Sophiris"

, a biopharmaceutical company developing PRX302 (topsalysin) for the treatment of urological diseases, today announced financial results for the three months ended March 31, 2015.
SPHS: 2.00 (-0.33)

Ritter Pharmaceuticals elects Gerald T Proehl to board
M2 - Thu Apr 23, 5:04AM CDT
Pharmaceutical company Ritter Pharmaceuticals disclosed on Wednesday the addition of Gerald T Proehl to its board of directors.
RTTR: 2.34 (-0.01), SPHS: 2.00 (-0.33), ASPX: 100.96 (unch)

Ritter Pharmaceuticals Names Gastroenterology Industry Veteran Gerald T. Proehl to its Board of Directors
Business Wire - Wed Apr 22, 7:30AM CDT
Ritter Pharmaceuticals, Inc., a privately held pharmaceutical company developing novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases, today announced that Gerald T. Proehl has joined the Company's Board of Directors. With his appointment, the Ritter Pharma Board now has seven Directors. Mr. Proehl will chair the Company's nominating and corporate governance committee.
TENX: 3.19 (unch), RTTR: 2.34 (-0.01), SPHS: 2.00 (-0.33), SLXP: 172.96 (+0.15)

Seeking Alpha's Biotech Weekly: A Biogen Deep Dive, Eisai's Arena Shuffle, And More
SA Editor Mike Taylor - at Seeking Alpha - Fri Apr 10, 3:00PM CDT
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. See something here that deserves further analysis? We are always looking for new...
BIIB: 280.18 (-3.35), SPHS: 2.00 (-0.33), ADMS: 15.31 (+0.02), TKMR: 10.83 (+0.58), CBYL: 3.84 (-0.01), HPTX: 45.99 (+0.02), QURE: 17.48 (+0.03), SHPG: 211.15 (+4.14), SRPT: 27.24 (+1.30), HZNP: 18.65 (-0.31), GALE: 1.47 (unch), JUNO: 53.00 (-0.47), ABBV: 60.34 (+0.33), CBMG: 22.80 (-0.09), ARNA: 1.73 (+0.03), EXEL: 5.62 (+0.14), ADXS: 11.98 (-0.40), PTLA: 49.71 (+0.02), BMY: 65.71 (+0.69), OCUL: 8.19 (-0.20), NVO: 53.89 (+0.63), DVA: 73.20 (-0.31), HALO: 15.75 (+0.17), GILD: 104.63 (+0.82), MRK: 53.78 (+0.08), AZN: 33.38 (+0.60), ALXN: 170.89 (+1.98), NVS: 87.57 (+0.52)

Sophiris Bio - Maybe Not A Left-For-Dead Biotech
JOHN PEABODY - at Seeking Alpha - Thu Apr 09, 3:47PM CDT

SPHS: 2.00 (-0.33)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Chemours Faces Class Action Over Fraud Allegations

Chemours and the Aftermarket Mirage When it rains, it pours, and for Chemours, the forecast isn't looking sunny. Investors are gearing up to slap Chemours Company (NYSE: CC) with a securities fraud class action. Why, you ask? Overstatement of aftermarket demand for refrigerants left investors high and dry after stock prices took an 18% nosedive. On August 4, 2026,...

Civista Welcomes Healthcare Leader to Boost Growth

Expanding the Boardroom with Healthcare Expertise In an unexpected twist for Civista Bancshares (NASDAQ: CIVB), the financial holding company is roping in some healthcare brass to its board. Jeremy Normington-Slay just snagged a seat at Civista's table, and he's bringing his tough-sledding healthcare leadership chops straight from Firelands Health. A $4.3 billion outfit...

mF International Shuts Down Legacy Business to Focus on BCH

mF International's Bold Digital Leap It’s a big move in the financial landscape when a firm decides to shake things up and pivot hard towards the digital frontier. mF International Limited (NASDAQ:MFI) is shutting the door on its legacy financial trading solutions and dedicating itself entirely to the budding world of digital assets. This isn’t just another facelift;...

Hyperliquid Expands Stock Buyback to $100 Million

Diving Into Hyperliquid's $100 Million Bold Move Let’s cut through the corporate fluff—Hyperliquid Strategies Inc. just cranked up their stock repurchase program to a cool $100 million. Yep, that’s right—the brain trust behind NASDAQ:PURR has pulled out the checkbook to buy more of its own shares. This decision, unveiled on October 23, 2026, is like tossing a...

Wisconsin Brats Clash with Florida Citrus in Marketing Showdown

A Juicy Rivalry with Sweet and Savory Stakes You ever catch yourself watching state pride turn into a marketing showdown? That's what's cookin' with Wisconsin's Johnsonville and Florida's Natural, and believe me, this isn't just about what’s on your plate. Forget the foam fingers, here it's all about the brats and the OJ. It's like the Packers versus the Dolphins, but...

Empire Steak House Expands to Delray Beach

Steakhouse Kings Bring New York Flavors to Florida When you're talking about steak, the Empire Steak House name carries some serious heft. This isn't just another restaurant chain cashing in on prime cuts; it's a family legacy over 21 years in the making. The Sinanaj Brothers, who honed their skills at Peter Luger in New York, are moving their empire south, landing a...

Galien Recognizes Kerry for Transformative Global Health Work

Kerry's Legacy: A Symbol of Global Unity In the ever-thickening jungle of geopolitics and global health, it's rare to find a beacon as steadfast as John Kerry. This year, The Galien Foundation saw fit to honor him with the 2026 Roy Vagelos Pro Bono Humanum Award for Global Health Equity. This ain't just some shiny trinket—it’s a testament to his lifetime of ripping...

Medicare Limits and Long-Term Care Planning Tips

Grappling with Medicare's Gaps Most folks hear Medicare and feel a sigh of relief—thinking it's a catch-all net for healthcare in your golden years. But hold on, when it comes to long-term care, Medicare's got more holes than Swiss cheese. Cindy Couyoumjian from Cinergy Financial lays it out pretty clear: Medicare doesn't cover what it calls 'custodial care'—you know,...

CSTS Unveils PremierX in NYC: A Bold Entertainment Move

Welcome to the New Era of Entertainment Out of the blockbusters and into the open air, eh? On October 30, 2026, CSTS Enterprises flipped the New York skyline into a canvas for their grand kickoff of PremierXTM—a live entertainment brand poised to redefine how we gobble up our music, sport, and art. Now, there's a shot of adrenaline New Yorkers weren't exactly begging...

COhatch Preps for High-Stakes Ohio Pitch Contest

Ohio Startups Gear Up for Another Fierce Faceoff You wouldn't find me betting against a hungry entrepreneur, especially with $25,000 on the line. That's the prize dangling at this year's Dublin Pitch Competition, hosted by COhatch and the City of Dublin. If there's one thing I'm certain of, it's that Ohio will see some real contenders stepping up on October 15....